AR084370A1 - Derivados de aminopirazol - Google Patents
Derivados de aminopirazolInfo
- Publication number
- AR084370A1 AR084370A1 ARP100102875A ARP100102875A AR084370A1 AR 084370 A1 AR084370 A1 AR 084370A1 AR P100102875 A ARP100102875 A AR P100102875A AR P100102875 A ARP100102875 A AR P100102875A AR 084370 A1 AR084370 A1 AR 084370A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- haloalkyl
- membered
- membered heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0805—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
Composiciones farmacéuticas y usos de los mismos. Reivindicación 1: Un compuesto representado por la formula (1), o una sal farmacéuticamente aceptable del mismo, en donde R1, R2, R3, y R4 cada uno representa independientemente el grupo que se lista más abajo: R1 representa hidrógeno, hidroxi, halógeno, ciano, nitro, haloalquilo C1-4, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-10 alquilo C1-4, -OR5, -NR6R7, -(CR8R9)nZ1, -C(O)NR12R13, -SR14, -SOR15, -SO2R16, -NR17SO2R18, COOH, arilo C6-10 que está opcionalmente sustituido con uno o más grupos seleccionados independientemente a partir del grupo P, heteroarilo de 5 a 10 miembros o heterociclilo de 3 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q, -COR19, -COOR20, -OC(O)R21, -NR22C(O)R23, -NR24C(S)R25, -C(S)NR26R27, -SO2NR28R29, -OSO2R30, -SO3R31, o -Si(R32)3; R2 representa hidrógeno, hidroxi, halógeno, ciano, nitro, haloalquilo C1-4, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, aril C6-10 alquilo C1-4, -OR5, -NR6R7, -(CR8R9)nZ1, -C(O)NR12R13, -SR14, -SOR15, -SO2R16, -NR17SO2R18, COOH, arilo C6-10 que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo P, heteroarilo de 5 a 10 miembros o heterociclilo de 3 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q, -COR19, -COOR20, -OC(O)R21, -NR22C(O)R23, -NR24C(S)R25, -C(S)NR26R27, -SO2NR28R29, -OSO2R30, -SO3R31, o -Si(R32)3; o R1 y R2, junto con un átomo al cual están unidos, forman heterociclilo de 3 a 10 miembros o heteroarilo de 5 a 10 miembros, en donde el heterociclilo o heteroarilo está opcionalmente sustituido con halógeno; R3 representa hidrógeno, alquilo C1-5, aril C6-10 alquilo C1-6 o haloalquilo C1-4; R4 representa hidrógeno, halógeno, alquilo C1-3, haloalquilo C1-4, hidroxi, ciano, nitro, alcoxi C1-4, -(CH2)nZ1, -NR6R7, -OR5, -C(O)NR12R13, -SR14, -SOR15, -SO2R16, NR17SO2R18, COOH, -COR19, -COOR20, -OC(O)R21, -NR22C(O)R23, -NR24C(S)R25, -C(S)NR26R27, -SO2NR28R29, -OSO2R30, -SO3R31, o -Si(R32)3; A representa un anillo heteroarilo de 5 a 10 miembros o anillo arilo C6-10; R5 representa alquilo C1-5, cicloalquilo C3-7, cicloalquilo C3-7 alquilo C1-3, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, alcoxi C1-3 alquilo C1-4, alcoxi C1-3alquilo C1-4, aminoalquilo C1-4, alquil C1-4amino-alquilo C1-4, di(alquil C1-4)amino-alquilo C1-4, arilo C6-10, aril C6-10alquilo C1-3, o heterociclil de 3 a 10 miembros-alquilo C1-3, heterociclilo de 3 a 10 miembros, heteroarilo de 5 a 10 miembros, heteroaril de 5 a 10 miembros-alquilo C1-3, monohidroxialquilo C1-6, dihidroxialquilo C1-6, o trihidroxialquilo C1-6 que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q; R6 y R7, que son iguales o diferentes, cada uno representa hidrógeno, alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, alcoxi C1-3alquilo C1-4, aril C6-10alquilo C1-3, heterociclil de 3 a 10 miembros-alquilo C1-3, heteroarilo de 5 a 10 miembros-alquilo C1-3, monohidroxialquilo C1-6, dihidroxialquilo C1-6, trihidroxialquilo C1-6, heterociclil de 3 a 10 miembros, aminoalquilo C1-4, alquil C1-4amino-alquilo C1-4, di(alquil C1-4)amino-alquilo C1-4, o ciano(alquilo C1-3); o R6 y R7, junto con un átomo de nitrógeno al cual están unidos, forman heterociclilo de 3 a 10 miembros o heteroarilo de 5 a 10 miembros; n representa 1 a 3; R8 y R9, que son iguales o diferentes, cada uno representa hidrógeno, alquilo C1-4, o halógeno; o alternativamente, R8 y R9, junto con un átomo de carbono al cual están unidos, forman un anillo cicloalifático; Z1 representa hidrógeno, NR10R11, -OH, o heterociclilo de 3 a 10 miembros o heteroarilo de 5 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q; R10 y R11, que son iguales o diferentes, cada uno representa alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, alcoxi C1-3alquilo C1-4, ciano(alquilo C1-3), o alquil C1-3sulfonil-alquilo C1-4 o alternativamente, R10 y R11, junto con un átomo de nitrógeno al cual están unidos, forman heterociclilo de 3 a 10 miembros o heteroarilo de 5 a 10 miembros; R12 y R13, que son iguales o diferentes, cada uno representa hidrógeno, alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, alcoxi C1-3alquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, heterociclilo de 3 a 10 miembros, aril C6-10alquilo C1-4, heterociclil de 3 a 10 miembros-alquilo C1-3, heteroarilo de 5 a 10 miembros-alquilo C1-3, ciano(alquilo C1-3), alquil C1-3sulfonilo-alquilo C1-4, anillo cicloalifático de 3 a 10 miembros, heteroarilo de 5 a 10 miembros, o heterociclilo de 3 a 10 miembros; o alternativamente, R12 y R13, junto con un átomo de nitrógeno al cual están unidos, forman heterociclilo de 3 a 10 miembros o heteroarilo de 5 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q; R14 representa alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo C6-10 que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo P, o heteroarilo de 5 a 10 miembros o heterociclilo de 3 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q; R15 representa alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo C6-10 que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo P, o heteroarilo de 5 a 10 miembros o heterociclilo de 3 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q; R16 representa alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo C6-10 que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo P, o heteroarilo de 5 a 10 miembros o heterociclilo de 3 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q; R17 representa hidrógeno o alquilo C1-4; R18 representa alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo C6-10 que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo P, o heteroarilo de 5 a 10 miembros o heterociclilo de 3 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q; R19 representa hidrógeno, alquilo C1-4, cicloalquilo C3-7, haloalquilo C1-4, arilo C6-10, o heteroarilo de 5 a 10 miembros o heterociclilo de 3 a 10 miembros que está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir del grupo Q; R20 representa alquilo C1-4, cicloalquilo C3-7, haloalquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, o heterociclilo de 3 a 10 miembros; R21 representa alquilo C1-4, cicloalquilo C3-7, haloalquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, o heterociclilo de 3 a 10 miembros; R22 representa hidrógeno, alquilo C1-4, o haloalquilo C1-4; R23 representa hidrógeno, alquilo C1-4, cicloalquilo C3-7, haloalquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, o heterociclilo de 3 a 10 miembros; R24 representa hidrógeno, alquilo C1-4, o haloalquilo C1-4; R25 representa alquilo C1-4, cicloalquilo C3-7, haloalquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, o heterociclilo de 3 a 10 miembros; R26 y R27, que son iguales o diferentes, cada uno representa hidrógeno, alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, alcoxi C1-3alquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, heterociclilo de 3 a 10 miembros, aril C6-10alquilo C1-4, heterociclilo de 3 a 10 miembros-alquilo C1-3, heteroarilo de 5 a 10 miembros-alquilo C1-3, ciano(alquilo C1-3), alquilo C1-3sulfonilo-alquilo C1-4, o un anillo cicloalifático de 3 a 10 miembros; o alternativamente, R26 y R27, junto con un átomo de nitrógeno al cual están unidos, forman heterociclilo de 3 a 10 miembros o heteroarilo de 5 a 10 miembros; R28 y R29, que son iguales o diferentes, cada uno representa hidrógeno, alquilo C1-4, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, alcoxi C1-3, alquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, heterociclilo de 3 a 10 miembros, aril C6-10alquilo C1-4, heterociclil de 3 a 10 miembros-alquilo C1-3, heteroaril de 5 a 10 miembros-alquilo C1-3, ciano(alquilo C1-3), alquil C1-3sulfonil-alquilo C1-4, o un anillo cicloalifático de 3 a 10 miembros; o alternativamente, R28 y R29, junto con un átomo de nitrógeno al cual están unidos, forman heterociclilo de 3 a 10 miembros o heteroarilo de 5 a 10 miembros; R30 representa alquilo C1-4, cicloalquilo C3-7, haloalquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, o heterociclilo de 3 a 10 miembros; R31 representa alquilo C1-4, cicloalquilo C3-7, haloalquilo C1-4, arilo C6-10, heteroarilo de 5 a 10 miembros, o heterociclilo de 3 a 10 miembros; R32 representa alquilo C1-4 o arilo C6-10;
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009184822 | 2009-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084370A1 true AR084370A1 (es) | 2013-05-15 |
Family
ID=43544423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102875A AR084370A1 (es) | 2009-08-07 | 2010-08-05 | Derivados de aminopirazol |
Country Status (28)
Country | Link |
---|---|
US (2) | US8829199B2 (es) |
EP (1) | EP2471786B1 (es) |
JP (2) | JP5225470B2 (es) |
KR (1) | KR101529767B1 (es) |
CN (1) | CN102574836B (es) |
AR (1) | AR084370A1 (es) |
AU (1) | AU2010279930B2 (es) |
BR (1) | BR112012008094A2 (es) |
CA (1) | CA2770195C (es) |
CL (1) | CL2012000324A1 (es) |
CY (1) | CY1117142T1 (es) |
DK (1) | DK2471786T3 (es) |
ES (1) | ES2561659T3 (es) |
HK (1) | HK1170236A1 (es) |
HR (1) | HRP20151258T1 (es) |
HU (1) | HUE028584T2 (es) |
IL (1) | IL217912A (es) |
IN (1) | IN2012DN01249A (es) |
MX (1) | MX2012001653A (es) |
MY (1) | MY163531A (es) |
PE (1) | PE20120795A1 (es) |
PL (1) | PL2471786T3 (es) |
PT (1) | PT2471786E (es) |
RU (1) | RU2580543C9 (es) |
SI (1) | SI2471786T1 (es) |
TW (1) | TWI464160B (es) |
WO (1) | WO2011016528A1 (es) |
ZA (1) | ZA201200895B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2561659T3 (es) | 2009-08-07 | 2016-02-29 | Chugai Seiyaku Kabushiki Kaisha | Derivados de aminopirazol |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
JP5963222B2 (ja) * | 2012-02-20 | 2016-08-03 | ローディア オペレーションズ | Dfmb誘導体の製造方法 |
UA117347C2 (uk) | 2012-06-13 | 2018-07-25 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
CN109627239B (zh) | 2012-07-11 | 2021-10-12 | 缆图药品公司 | 成纤维细胞生长因子受体的抑制剂 |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US10689705B2 (en) * | 2012-09-27 | 2020-06-23 | Chugai Seiyaku Kabushiki Kaisha | FGFR3 fusion gene and pharmaceutical drug targeting same |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
CN105263931B (zh) | 2013-04-19 | 2019-01-25 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
CN103224479B (zh) * | 2013-04-26 | 2014-10-15 | 温州大学 | 一种2-芳基苯并呋喃类化合物的合成方法 |
CA2919075A1 (en) * | 2013-07-31 | 2015-02-05 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions with improved gelation properties comprising an anti-cancer aminopyrazole and alkyl sulfate salt |
EP3395814B1 (en) | 2013-10-25 | 2022-04-06 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
MX2016006351A (es) * | 2013-12-13 | 2016-08-01 | Hoffmann La Roche | Inhibidores de tirosina cinasa de bruton. |
KR101768402B1 (ko) | 2013-12-13 | 2017-08-14 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나제의 억제제 |
US9624201B2 (en) * | 2013-12-13 | 2017-04-18 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
ES2756175T3 (es) | 2013-12-27 | 2020-04-27 | Chugai Pharmaceutical Co Ltd | Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
CA2943405A1 (en) | 2014-03-31 | 2015-10-08 | Debiopharm International Sa | Fgfr fusions |
AU2015286049B2 (en) * | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
RU2658821C1 (ru) | 2014-08-18 | 2018-06-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соль моноциклического производного пиридина и ее кристалл |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
UA121669C2 (uk) | 2015-02-20 | 2020-07-10 | Інсайт Корпорейшн | Біциклічні гетероцикли як інгібітори fgfr |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016204261A1 (ja) * | 2015-06-17 | 2016-12-22 | 中外製薬株式会社 | アミノピラゾール誘導体 |
BR112018001438A2 (pt) | 2015-07-24 | 2018-12-04 | Debiopharm International S.A. | expressão de fgfr e suscetibilidade a um inibidor de fgfr |
WO2017028816A1 (zh) * | 2015-08-20 | 2017-02-23 | 浙江海正药业股份有限公司 | 吲哚类衍生物及其制备方法和其在医药上的用途 |
WO2017157332A1 (zh) * | 2016-03-18 | 2017-09-21 | 江苏恒瑞医药股份有限公司 | 芳香酰胺类衍生物、其制备方法及其在医药上的应用 |
CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3777860A4 (en) | 2018-03-28 | 2021-12-15 | Eisai R&D Management Co., Ltd. | THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA |
SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
CN110092791B (zh) * | 2019-05-17 | 2020-04-03 | 河南大学 | 5,6-吲哚并二恶烷类衍生物及其制备方法和应用 |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN112358435B (zh) * | 2019-10-12 | 2023-01-10 | 中国医学科学院医药生物技术研究所 | 取代芳并杂环类化合物、制备方法和抑制ulk1及抗肿瘤用途 |
PE20221085A1 (es) | 2019-10-14 | 2022-07-05 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
TW202333686A (zh) * | 2021-12-08 | 2023-09-01 | 美商奇奈特生物製藥公司 | 以fgfr激酶抑制劑治療癌症 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0170567B1 (ko) | 1992-12-17 | 1999-02-18 | 알렌 제이. 스피겔 | 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘 |
US6316466B1 (en) * | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
AU765030B2 (en) | 1998-05-05 | 2003-09-04 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as p-38 map kinase inhibitors |
WO2001012600A1 (en) * | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
JP2003050945A (ja) | 2001-08-06 | 2003-02-21 | Takashi Hashimoto | 連動型広告配信システム及び広告配信サーバの動作方法 |
FR2831537B1 (fr) * | 2001-10-26 | 2008-02-29 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation |
BR0213562A (pt) | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
FR2854159B1 (fr) | 2003-04-25 | 2008-01-11 | Aventis Pharma Sa | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
CN1832928B (zh) * | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
WO2006134318A1 (en) | 2005-06-11 | 2006-12-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
WO2007077435A1 (en) | 2005-12-30 | 2007-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
FR2903406B1 (fr) | 2006-07-04 | 2012-08-10 | Aventis Pharma Sa | Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation |
RU2011106357A (ru) * | 2008-07-23 | 2012-08-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Гетероциклические антивирусные соединения |
BRPI0916233A2 (pt) * | 2008-07-23 | 2018-03-13 | F.Hoffman-La Roche Ag | compostos heterocíclicos antivirais |
ES2561659T3 (es) | 2009-08-07 | 2016-02-29 | Chugai Seiyaku Kabushiki Kaisha | Derivados de aminopirazol |
-
2010
- 2010-08-05 ES ES10806527.7T patent/ES2561659T3/es active Active
- 2010-08-05 EP EP10806527.7A patent/EP2471786B1/en active Active
- 2010-08-05 US US13/389,146 patent/US8829199B2/en active Active
- 2010-08-05 RU RU2012108164/04A patent/RU2580543C9/ru active
- 2010-08-05 DK DK10806527.7T patent/DK2471786T3/en active
- 2010-08-05 MY MYPI2012000478A patent/MY163531A/en unknown
- 2010-08-05 CA CA2770195A patent/CA2770195C/en not_active Expired - Fee Related
- 2010-08-05 TW TW099126056A patent/TWI464160B/zh not_active IP Right Cessation
- 2010-08-05 HU HUE10806527A patent/HUE028584T2/en unknown
- 2010-08-05 WO PCT/JP2010/063315 patent/WO2011016528A1/ja active Application Filing
- 2010-08-05 JP JP2011525936A patent/JP5225470B2/ja active Active
- 2010-08-05 AR ARP100102875A patent/AR084370A1/es active IP Right Grant
- 2010-08-05 CN CN201080045256.4A patent/CN102574836B/zh not_active Expired - Fee Related
- 2010-08-05 BR BR112012008094-6A patent/BR112012008094A2/pt not_active Application Discontinuation
- 2010-08-05 PT PT108065277T patent/PT2471786E/pt unknown
- 2010-08-05 AU AU2010279930A patent/AU2010279930B2/en not_active Ceased
- 2010-08-05 PE PE2012000181A patent/PE20120795A1/es active IP Right Grant
- 2010-08-05 IN IN1249DEN2012 patent/IN2012DN01249A/en unknown
- 2010-08-05 SI SI201031114T patent/SI2471786T1/sl unknown
- 2010-08-05 PL PL10806527T patent/PL2471786T3/pl unknown
- 2010-08-05 KR KR1020127005218A patent/KR101529767B1/ko active IP Right Grant
- 2010-08-05 MX MX2012001653A patent/MX2012001653A/es active IP Right Grant
-
2012
- 2012-02-02 IL IL217912A patent/IL217912A/en active IP Right Grant
- 2012-02-06 ZA ZA2012/00895A patent/ZA201200895B/en unknown
- 2012-02-07 CL CL2012000324A patent/CL2012000324A1/es unknown
- 2012-10-31 HK HK12110953.0A patent/HK1170236A1/xx not_active IP Right Cessation
-
2013
- 2013-01-31 JP JP2013017346A patent/JP5732081B2/ja active Active
-
2014
- 2014-06-06 US US14/297,790 patent/US9102692B2/en active Active
-
2015
- 2015-11-23 HR HRP20151258TT patent/HRP20151258T1/hr unknown
-
2016
- 2016-01-18 CY CY20161100044T patent/CY1117142T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084370A1 (es) | Derivados de aminopirazol | |
AR082763A1 (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer | |
AR094174A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. | |
AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
AR094704A1 (es) | Compuestos y composiciones como degradantes selectivos del receptor de estrógeno | |
AR044401A1 (es) | Compuestos derivados de quinoleina, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos. | |
AR072488A1 (es) | Derivados heterociclicos de 1,2,4-triazol, agonistas de receptores beta 2 adrenergicos y antagonistas muscarinicos colinergicos, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de afecciones respiratorias, inflamatorias y alergicas. | |
AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
AR095609A1 (es) | Compuestos de pirrolopiridina | |
AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
AR078121A1 (es) | Compuestos de sales de amonio cuaternario y composiciones farmaceuticas | |
RU2010129238A (ru) | Применение производных изотиоцианата в качестве противомиеломных средств | |
JP2016503797A5 (es) | ||
AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
RU2016135922A (ru) | Терапевтические соединения и композиции | |
AR082633A1 (es) | Analogos de tetraciclina | |
AR078549A1 (es) | Antagonistas de la via de wnt y composiciones farmaceuticas que los contienen | |
AR078164A1 (es) | Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |